ODI Pharma announced on October 30th that the company has resolved to carry out a rights issue of approximately SEK 4.1m before transaction costs, with an option for an over-allotment of an additional SEK 2.0m. The issue is expected to be approved at an extraordinary general meeting on November 19, 2024.

Link to the analysis